Bionano Genomics Files 8-K on Financials
Ticker: BNGO · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1411690
| Field | Detail |
|---|---|
| Company | Bionano Genomics, Inc. (BNGO) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: BNGO
TL;DR
BNGO dropped an 8-K detailing their financials - check it for the latest numbers.
AI Summary
Bionano Genomics, Inc. filed an 8-K on October 10, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status and operational performance.
Why It Matters
This filing provides investors and stakeholders with crucial, up-to-date information on Bionano Genomics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material financial information that can lead to significant stock price volatility.
Key Players & Entities
- Bionano Genomics, Inc. (company) — Registrant
- October 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices address
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the excerpt.
When was the earliest event reported in this filing?
The earliest event reported is dated October 10, 2024.
What is the principal executive office address for Bionano Genomics, Inc.?
The principal executive offices are located at 9540 Towne Centre Drive, Suite 100, San Diego, California, 92121.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is the SIC code for Bionano Genomics, Inc.?
The Standard Industrial Classification (SIC) code for Bionano Genomics, Inc. is 3826, which corresponds to Laboratory Analytical Instruments.
Filing Stats: 1,000 words · 4 min read · ~3 pages · Grade level 14 · Accepted 2024-10-10 08:10:14
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq
Filing Documents
- ef20037106_8k.htm (8-K) — 33KB
- ef20037106_ex99-1.htm (EX-99.1) — 15KB
- image00003.jpg (GRAPHIC) — 2KB
- image00004.jpg (GRAPHIC) — 2KB
- 0001140361-24-043244.txt ( ) — 194KB
- bngo-20241010.xsd (EX-101.SCH) — 4KB
- bngo-20241010_lab.xml (EX-101.LAB) — 21KB
- bngo-20241010_pre.xml (EX-101.PRE) — 16KB
- ef20037106_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Conditions. On October 10, 2024, Bionano Genomics, Inc. (the "Company") issued a press release reporting its preliminary financial results for the third quarter ended September 30, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided in this Item 2.02 of this Current Report on Form 8-K shall be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and it shall be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and the press release filed herewith contain "forward-looking statements"within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Words such as "believe," "can," "could," "may" "potential" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's expectations for third quarter 2024 revenue and potential impairments, write downs, and other non-cash or cash charges which may affect the Company's third quarter 2024 financial results. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include adjustments to our preliminary measures of financial performance resulting from, among other things, the completion of our end-of-period review and reporting processes; the impact of adverse geopolitical and macroeconomic events, such as recent and future bank failures, the ongoing Ukraine-Russia conflict, related sanctions and any global pandemics, on our business and the global economy; challenges inherent in developing, manufacturing and commercializing products; our ability to further deploy new products and applications and expand the markets for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; changes in our strategic and commercial plans; our ability to continue as a going concern, which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commer
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued October 10, 2024. 104 Inline XBRL for the cover page of this Current Report on Form 8-K
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: October 10, 2024 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive and Financial Officer)